Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Recommendation of “Moderate Buy” from Analysts

Roivant Sciences Ltd. (NASDAQ:ROIV) has been given an average rating of “Moderate Buy” by the ten brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $17.10.

ROIV has been the subject of a number of research reports. Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a research report on Tuesday, June 18th. Piper Sandler boosted their target price on Roivant Sciences from $20.00 to $22.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a research report on Monday, August 19th.

Institutional Investors Weigh In On Roivant Sciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Headlands Technologies LLC acquired a new stake in shares of Roivant Sciences in the fourth quarter worth $36,000. Swiss National Bank boosted its holdings in Roivant Sciences by 8.1% during the fourth quarter. Swiss National Bank now owns 546,746 shares of the company’s stock valued at $6,140,000 after acquiring an additional 41,000 shares during the period. Natixis Advisors L.P. bought a new stake in Roivant Sciences during the fourth quarter valued at about $699,000. Charles Schwab Investment Management Inc. grew its position in shares of Roivant Sciences by 5.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,023,027 shares of the company’s stock valued at $22,719,000 after purchasing an additional 99,148 shares during the last quarter. Finally, E Fund Management Co. Ltd. increased its stake in shares of Roivant Sciences by 34.6% in the fourth quarter. E Fund Management Co. Ltd. now owns 48,860 shares of the company’s stock worth $549,000 after purchasing an additional 12,569 shares during the period. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Roivant Sciences Stock Performance

Shares of ROIV opened at $12.23 on Friday. The company has a 50-day moving average of $11.07 and a two-hundred day moving average of $11.00. The stock has a market cap of $9.03 billion, a price-to-earnings ratio of 2.42 and a beta of 1.24. The company has a debt-to-equity ratio of 0.07, a current ratio of 25.24 and a quick ratio of 25.24. Roivant Sciences has a one year low of $8.24 and a one year high of $13.24.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.33. The firm had revenue of $55.10 million for the quarter, compared to analysts’ expectations of $30.72 million. Roivant Sciences had a net margin of 3,484.86% and a negative return on equity of 25.05%. The company’s quarterly revenue was up 155.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.38) EPS. On average, equities research analysts expect that Roivant Sciences will post -1.12 earnings per share for the current year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.